Maviret (Glecaprevir, Pibrentasvir)

Glecaprevir/pibrentasvir, the active ingredient in Maviret, is a NS3/4A protease inhibitor and NS5A inhibitor presented as a 100 mg glecaprevir / 40 mg pibrentasvir tablet for oral use. It treats chronic hepatitis C virus infection across genotypes 1‑6 in adult patients, including those with compensated cirrhosis.

GNH USA supplies Maviret as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, pharmacies and clinics worldwide.

Maviret is indicated for the treatment of chronic hepatitis C virus (HCV) infection, a viral liver disease.

Chronic hepatitis C virus infection (genotypes 1‑6): provides a high rate of sustained virologic response in adult patients. Compensated cirrhosis due to HCV (genotypes 1‑6): enables viral eradication while preserving liver function. Previous HCV therapy failure (genotypes 1‑6): offers an effective rescue regimen for patients previously treated with other antivirals.

Maviret may cause a range of adverse reactions.

Common Side Effects: - Headache: mild to moderate intensity. - Fatigue: persistent tiredness reported by some patients. - Nausea: occasional upset stomach. - Diarrhea: loose stools during treatment. - Abdominal pain: discomfort in the stomach area. - Pruritus: itching of the skin.

Serious or Rare Side Effects: - Elevated liver enzymes: significant increase indicating liver stress. - Hepatic decompensation: worsening liver function in susceptible individuals. - Severe rash or allergic reaction: including Stevens‑Johnson syndrome. - Anemia: notable drop in red blood cell count. - Renal impairment: reduced kidney function in rare cases.

Before initiating Maviret, clinicians should consider several safety measures.

Assess liver function: evaluate baseline hepatic enzymes and cirrhosis status. Monitor for drug‑drug interactions: review concomitant medications, especially strong CYP3A inducers. Pregnancy and lactation: avoid use unless benefits outweigh potential risks; limited data are available. Renal impairment: exercise caution in patients with severe renal dysfunction and monitor renal parameters. Store at ambient temperature: keep below 25°C, retain original packaging, protect from moisture.

Maviret has notable interactions that require attention.

Major Interactions (Avoid): - Strong CYP3A inducers (e.g., rifampin, carbamazepine, St. John’s wort): may markedly reduce drug exposure. - Co‑administration with contraindicated HCV agents that share overlapping metabolic pathways.

Moderate Interactions (Monitor Closely): - Moderate CYP3A inhibitors (e.g., erythromycin, clarithromycin): may increase plasma levels. - Certain statins (e.g., simvastatin, lovastatin): risk of increased statin exposure and myopathy. - Antacids containing aluminum or magnesium: may decrease absorption of the tablet.